Platinum Asset Management (PTM)
|
|
- Ilene Taylor
- 5 years ago
- Views:
Transcription
1 24 February 2017 Analyst Lafitani Sotiriou Associate Analyst James Filius Authorisation TS Lim Recommendation Hold (unchanged) Price $5.10 Target (12 months) $4.90 (previously $4.75) Expected Return Capital growth -3.9% Dividend yield 5.9% Total expected return 2.0% Company Data & Ratios Enterprise value Market cap $2,742m $2,992m Issued capital 586.7m Free float 41% Avg. daily val. (52wk) $9,485, month price range $4.64-$6.75 GICS sector Price Performance Diversified Financials (1m) (3m) (12m) Price (A$) Absolute (%) Rel market (%) Platinum Asset Management (PTM) Cutting buyback from our numbers Better result, offset by removing buyback estimate PTM has delivered a better than expected 1H17 result, 3.4% ahead of our estimate. However, much of the resetting of our earnings has been offset by the removal of any buyback in our numbers. In September 2016 PTM announced, for the first time in recent years, the commencement of an on-market share buyback program. Unfortunately the announcement has been followed by inaction, despite there being enough cash to do so and there having been share price weakness since the announcement. As such, we have removed any estimate of a Buyback, and this has largely offset the benefit of the slight beat in the result. Overall we remain cautious on PTM, given the significant level of fund outflows in the last year, however believe the current dividend of ~6.0% provides support to the share price at current levels and maintain our Hold recommendation. Result highlights 1H17 underlying NPAT down 15.1% vs pcp to $94.2m, 3.4% ahead our estimate; 1H17 reported NPAT of $97.5m, down 18.5% vs pcp, ahead $91.1 BPe; Net-flows for the half -$1.7 billion, retail fund outflows -$1.4 billion; Cost to fee ratio remains constrained at 15%, vs 14% pcp; and Interim dividend of 15cps (fully franked) vs our estimate of 14cps. Earnings revisions Following the 1H17 result, we have subtly upgraded our underlying EPS by 1.0%, - 0.1% and 0.8% for FY17, FY18 and FY19 respectively. The revisions are largely driven by a better 1H17 result than anticipated, offset to a large degree by the removal of any buyback from our estimates. We have increased our Price Target slightly to $4.90 per share (previously $4.75) and retain our Hold recommendation. Absolute Price $10.0 $9.0 $8.0 $7.0 $6.0 $5.0 $4.0 $3.0 Feb 15 Aug 15 Feb 16 Aug 16 Feb 17 PTM S&P 300 Rebased SOURCE: IRESS Earnings Forecast Year end June e 2018e 2019e Sales revenue (A$m) EBITDA (A$m) NPAT (adjusted) (A$m) EPS (adjusted) (cps) EPS growth (%) -3% -10% 4% 4% PER (x) Price/book (x) EV/EBITDA (x) Price/CF (x) Dividend ( ps) Yield (%) 6.3% 5.9% 6.1% 6.3% ROE (%) 55.5% 48.5% 48.9% 49.6% Franking (%) 100.0% 100.0% 100.0% 100.0% SOURCE: BELL POTTER SECURITIES ESTIMATES BELL POTTER SECURITIES LIMITED ACN AFSL DISCLAIMER AND DISCLOSURES THIS REPORT MUST BE READ WITH THE DISCLAIMER AND DISCLOSURES ON PAGE 6 THAT FORM PART OF IT. Page 1
2 PTM FUM & Net-flows Figure 1 Annual and Half year Net-flows ($m) Figure 2 - Funds Under Management (FUM) ($m) Annual Net-Flows HalfYear Net-Flows FY12 FY13 FY14 FY15 FY16 1H16 2H16 1H17 32,000 30,000 28,000 26,000 24,000 22,000 20,000 18,000 16,000 14,000 Retail Institutional SOURCE: COMPANY DATA SOURCE: COMPANY DATA Figure 3 - PTM Funds Under Management ($m) Platinum (PTM) 2014a 1H15a 2H15a 2015a 1H16a 2H16a 2016a 1H17a 2H17f 2017f 1H18f 2H18f 2018f Jun-14 Dec-14 Jun-15 Jun-15 Dec-15 Jun-16 Jun-16 Dec-16 Jun-17 Jun-17 Dec-17 Jun-18 Jun-18 FUM (A$m) Platinum Trust Funds Open 13,170 15,861 18,207 15,861 19,117 19,105 19,117 16,539 Flow s ,318 distributions ,425-1, Market 2,240 1,844 1,926 3, ,481 1,528 Close 15,861 18,207 19,117 19,117 19,105 16,539 16,539 16,749 MLC - Platinum Global Fund Open 1,028 1,079 1,089 1,079 1,113 1,045 1, Flow s distributions Market Close 1,079 1,089 1,113 1,113 1, Management Fee Mandates Open 1,964 2,119 2,178 2,119 1,977 1,968 1,977 1,849 Flow s distributions Market Close 2,119 2,178 2,375 2,375 1,968 1,849 1,849 1,973 Performance Share Fee Mandates (absolute) Open Flow s distributions Market Close Performance Share Fee Mandates (relative) Open 3,002 3,190 3,515 3,190 3,545 3,361 3,545 2,218 Flow s , distributions Market Close 3,190 3,515 3,545 3,545 3,361 2,218 2,218 2,315 Total FUM Open 19,764 22,942 25,724 22,942 26,859 26,785 26,461 22,688 23,178 22,688 23,271 24,041 23,271 Flow s ,867-1,440-1, , distributions ,425-1, Market 3,451 2,514 2,748 5, ,323-1,824 2, , ,870 Close 22,942 25,724 26,859 26,859 26,785 22,688 22,688 23,178 23,271 23,271 24,041 24,341 24,341 SOURCE: COMPANY DATA Page 2
3 Interim earnings & estimate revisions Interim earnings Figure 4 - Interim earnings INCOME STATEMENT Y/e June 30 ($m) 1H16 2H H17 2H17e 2017e 1H18e 2H18e 2018e 1H19e 2H19e 2019e Sales revenue Operating Expenses EBITDA Depreciation & Amortisation EBIT Net Interest Pre-tax profit Tax Adjusted profit One-off items Reported net profit ASSUMPTIONS Y/e June 30 1H16 2H H17 2H17e 2017e 1H18e 2H18e 2018e 1H19e 2H19e 2019e FUM movements ($m) Open 26,859 26,785 26,461 22,688 23,178 22,688 23,271 24,041 23,271 24,341 25,001 24,341 Net-flows 427-1,867-1,440-1, , Distribution Market ,323-1,824 2, , , ,946 Close 26,785 22,688 22,688 23,178 23,271 23,271 24,041 24,341 24,341 25,001 25,187 25,187 Growth (%) 0% -15% -16% 2% 0% 3% 3% 1% 5% 3% 1% 3% Average FUM ($m) 27,165 24,432 25,798 23,328 23,369 23,348 23,718 24,422 24,070 24,724 25,316 25,020 Revenue ($m) Management Fees Performance Fees Administration Fees Total Fees DPS (cps) Franking 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Figure 5 - Earnings revisions SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Earnings revisions Following the 1H17 result, we have subtly upgraded our underlying EPS by 1.0%, -0.1% and 0.8% for FY17, FY18 and FY19 respectively. The revisions are largely driven by a better 1H17 result than anticipated, offset to a large degree by the removal of any buyback from our estimates. Earnings Revisions FY17e FY17e (new) (previous) % Change FY18e FY18e (new) (previous) % Change FY19e FY19e (new) (previous) % Change EPS (underlying) cps % % % Dividend ( ps) % % % Page 3
4 Platinum Asset Management overview Company description Platinum is an investment manager. The flagship product is the Platinum International Fund which has historically outperformed relative to its benchmark. However, the last two years have been difficult for the fund with it delivering negative absolute and index relative returns. The company is based in Australia, with only the one office in Sydney, catering for 70 employees. Listed on the ASX, only 37% of the stock is free float. Investment case We remain concerned around net-flows, as we estimate these are still negative. However, the improving performance and lower share price justifies our Hold recommendation. Risks We see the main risks for Platinum as: Key people risk Similar to other wealth management businesses, the loss of any key investment personnel may result in the loss of investment mandates. This is particularly relevant for Platinum, with the majority shareholder and driving person behind the firm, Kerr Neilson, carrying a large risk should anything happen to him, or he decide to leave; Performance risk Investors are wary of investment managers that charge active management fees and that have underperformed the index over a prolonged period of time. It is important for Platinum to maintain reputable performance metrics across its product offering; Market risk Share market levels can be impacted by a range of exogenous factors such as interest rates, inflation, currency movements and general global events. Any significant movements in equity prices can have a material impact on PTM earning; Currency risk Significant currency variations may impact the underlying performance of PTM funds ; and Regulatory risk PTM invests in in varying countries and global markets. Any changes to legislation or regulations may significantly impact the company and the financial performance of PTM and the value of its funds. Page 4
5 Platinum Asset Management Platinum Asset Management (PTM) 24 February 2017 as at 24 February 2017 Recommendation Hold Price $5.10 Target (12 months) $4.90 Table 1 - Financial summary Platinum (PTM) Price Target (A$) 4.90 Share Price (A$) 5.10 Recommendation: Hold Market Cap (A$b) 3.0 INCOME STATEMENT VALUATION DATA Y/e June 30 ($m) e 2018e 2019e Y/e June 30 ($m) e 2018e 2019e Sales revenue Net profit adj ($m) Operating Expenses Adjusted EPS (c) EBITDA EPS growth (%) 6% -3% -10% 4% 4% Depreciation & Amortisation P/E ratio (x) EBIT CFPS (c) Net Interest Price/CF (x) Pre-tax profit DPS (c) Tax Yield (%) 9.2% 6.3% 5.9% 6.1% 6.3% Adjusted profit Franking (%) 100% 100% 100% 100% 100% One-off items EV/EBITDA (x) Reported net profit Price/book (x) NTA ($) CASHFLOW Y/e June 30 ($m) e 2018e 2019e PROFITABILITY RATIOS EBITDA Y/e June 30 ($m) e 2018e 2019e Change in provisions EBIT/sales (%) 82.7% 81.5% 80.4% 80.6% 80.8% Working capital change Return on assets (%) 72.6% 72.7% 63.8% 64.6% 65.5% Net interest Return on equity (%) 56.5% 55.5% 48.5% 48.9% 49.6% Tax paid Dividend cover (x) Other Effective tax rate (%) 29.2% 29.2% 29.5% 29.5% 29.5% Operating cashflow Capex LIQUIDITY AND LEVERAGE RATIOS Investments Y/e June 30 ($m) e 2018e 2019e Asset sales Net debt/(cash) ($m) Other Net debt/equity (%) -94% -71% -67% -67% -68% Investing cashflow Current ratio (x) Equity raised Dividends paid INTERIMS Other Half end December 31 ($m) 1H15 1H16 1H17 1H18e 2019e Financing cashflow Sales revenue Net change in cash EBIT Cash at end of period Pre tax profit Adjusted profit BALANCE SHEET One-off items Y/e June 30 ($m) e 2018e 2019e Reported profit Cash Interim DPS (cents) Receivables Interim adjusted EPS (cents) PPE Intangibles ASSUMPTIONS Other Y/e June e 2018e 2019e Total assets Payables FUM movements ($m) Debt Open 22,942 26,461 22,688 23,271 24,341 Provisions Flows, distributions and market 3,917-3, , Other Close 26,859 22,688 23,271 24,341 25,187 Total liabilities Growth (%) 17% -16% 3% 5% 3% Shareholders equity Total shareholders funds Average FUM ($m) 26,148 25,798 23,348 24,070 25,020 W/A shares on issue Revenue ($m) Management Fees Performance Fees Administration Fees Total Fees SOURCE: BELL POTTER SECURITIES ESTIMATES Page 5
6 Recommendation structure Buy: Expect >15% total return on a 12 month view. For stocks regarded as Speculative a return of >30% is expected. Research Team Staff Member TS Lim Sam Haddad Jonathon Higgins Title/Sector Head of Research Phone tslim shaddad jhiggins Hold: Expect total return between -5% John O Shea joshea and 15% on a 12 month view Chris Savage csavage Sell: Expect <-5% total return on a 12 month view Jonathan Snape Tim Piper John Hester Healthcare jsnape tpiper jhester Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet. Such investments may carry an Tanushree Jain Financials TS Lim Lafitani Sotiriou Resources Peter Arden David Coates Associates James Filius Healthcare/Biotech Banks/Regionals Diversified Resources Resources Associate Analyst tnjain tslim lsotiriou parden dcoates jfilius exceptionally high level of capital risk and volatility of returns. Bell Potter Securities Limited ACN Level 38, Aurora Place 88 Phillip Street, Sydney 2000 Telephone The following may affect your legal rights. Important Disclaimer: This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client s financial situation, particular needs and investment objectives ( relevant personal circumstances ), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arraignment with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. ANALYST CERTIFICATION Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Page 6
Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions
16 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation TS Lim 612 8224 2810 Perpetual (PPT) Oversold, upgrade to Buy Recommendation Buy (Hold) Price $42.09 Target (12 months) $47.50 (previously
More informationOneVue Holdings (OVH)
7 August 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 OneVue Holdings (OVH) FY17 result to show cost-out progress Recommendation
More informationOneVue Holdings (OVH)
24 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation Peter Arden 613 9235 1833 OneVue Holdings (OVH) Restructured and focused Recommendation Buy (unchanged) Price $0.745 Target (12 months)
More informationAdacel Technologies (ADA)
9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously
More informationNanosonics (NAN) Preparing for new international markets. Maintain Hold, price target amended to $3.20 SOURCE: BELL POTTER SECURITIES ESTIMATES
21 February 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) Growth Slowly Emerging In Europe Recommendation Hold (unchanged) Price $2.80 Target (12 months) $3.20
More informationBWX Limited (BWX) SOURCE: BELL POTTER SECURITIES ESTIMATES
9 February 2017 Analyst John O'Shea 613 9235 1633 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $4.80 Target (12 months) $5.73 (unchanged) Expected Return Capital growth
More informationChallenger (CGF) Expanding the potential. A broader and more robust business emerging. Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES
14 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Challenger (CGF) Expanding the potential Recommendation Buy (unchanged)
More informationMayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17.
29 June 2016 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Mayne Pharma (MYX) Merger Fallout Creates Opportunity Recommendation Buy (unchanged) Price $1.485 Target (12 months) $1.89
More informationNanosonics (NAN) Summary of 2Q17 Cash Flows SOURCE: BELL POTTER SECURITIES ESTIMATES
16 January 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) US Market Continues To Expand Recommendation Hold (unchanged) Price $3.16 Target (12 months) $3.28
More informationSurfStitch (SRF) Shaping the Surf industry. Acquisition in Product drives credibility. however we have some concerns
26 November 20 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 SurfStitch (SRF) Shaping the Surf industry Recommendation Buy (unchanged) Price $2.06 Target (12 months) $2.65 (previously
More informationOsprey (OSP) FY16 EBITDA Loss In Line. OSP has US$21.8m of cash as at 31 December Maintain Buy Rating And Valuation at $0.55
27 February 2017 Analyst John Hester 612 8224 2871 Authorisation Tanushree Jain 612 8224 2849 Recommendation Buy (unchanged) Price $0.415 Valuation $0.55 (unchanged) Risk Speculative GICS Sector Healthcare
More informationANZ Bank (ANZ) Unquestionably strong 1Q17. Healthy Jaws, safe to go back in the water SOURCE: BELL POTTER SECURITIES ESTIMATES
17 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 ANZ Bank (ANZ) Unquestionably strong 1Q17 Recommendation Buy (Hold) Price $30.21 Target (12 months) $33.25 (previously
More informationFortescue Metals Group Ltd (FMG)
3 March 2017 Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Fortescue Metals Group Ltd (FMG) All about the iron ore price Recommendation Sell (unchanged) Price $6.62 Target
More informationCyclopharm (CYC) Entry to US market inching closer. Maintain Buy Recommendation SOURCE: BELL POTTER SECURITIES ESTIMATES
Analyst John Hester 612 8224 2871 Cyclopharm (CYC) 5 March 2018 Speculative See key risks on Page 4 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.
More informationIPH Limited (IPH) Buy at the bottom
29 March 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 IPH Limited (IPH) Buy at the bottom Recommendation Buy (unchanged) Price $4.76 Target (12 months) $7.90 (unchanged) Expected
More informationAuswide Bank (ABA) There are no tricks in plain and simple faith. 24 August : Underlying NPAT $17m, final dividend 18cps
24 August 2018 TS Lim 612 8224 2810 Authorisation Tim Piper 612 8224 2825 Recommendation Buy (unchanged) Price $5.71 Target (12 months) $6.20 (previously $5.80) GICS Sector Banks Expected Return Capital
More informationANZ Banking Group (ANZ)
1 May 2018 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $27.47 Target (12 months) $30.20 (unchanged) GICS Sector Banks Expected Return Capital
More informationNational Australia Bank (NAB)
6 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $30.39 Target (12 months) $32.50 (previously $30.00) Expected Return Capital growth
More informationPremier Investments (PMV)
16 March 2018 Analyst Sam Haddad 612 8224 2819 Authorisation Tim Piper 612 8224 2825 Premier Investments (PMV) Key growth pillars all strong Recommendation Buy (unchanged) Price $15.27 Target (12 months)
More informationAeon Metals Limited (AML)
Analyst David Coates 612 8224 2887 Authorisation Stuart Howe 613 9235 1856 Speculative See key risks on Page 4 Speculative securities may not be suitable for retail clients 22 March 2019 Aeon Metals Limited
More informationWestgold Resources (WGX)
3 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.36 Target (12 months) $2.15 (unchanged) Expected Return Capital growth
More informationCommonwealth Bank (CBA)
10 February 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Commonwealth Bank (CBA) Ordeal and triumph Recommendation Buy (unchanged) Price $74.20 Target (12 months) $83.50 (previously
More informationMetals X Limited (MLX)
16 July 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.655 Target (12 months) $0.95 (previously $0.98) Expected Return Capital growth
More informationPeet Bonds (PPCHA) A yield uplift from fixed rate senior debt
4 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 (PPCHA) Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code Peet PPCHA Face value $100 Estimated
More informationMetals X Limited (MLX)
5 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.515 Target (12 months) $0.90 (previously $0.95) Expected Return Capital
More informationOsprey Medical (OSP)
18 October 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Osprey Medical (OSP) Harvey and Irma Curtail Growth Speculative See key risks on Page 5 and Biotechnology Risk Warning
More informationNational Australia Bank (NAB)
29 March 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $25.62 Target (12 months) $29.50 (unchanged) Expected Return Capital growth 15.1%
More informationGalaxy Resources Ltd (GXY)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $1.835 Valuation $3.35 (unchanged) -------------- Risk Speculative Expected Return Capital
More informationTech Sector. Updated key sells: None. Company Ticker Share price at Market Year end 22-Mar-17 cap FY17a/CY17e FY18e/CY18e FY17a/CY17e FY18e/CY18e
22 March 2017 Analyst Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Tech Sector Key picks unchanged: IRI, APX, ADA & IFM Stock Price Target Rating ADA $2.37 $3.25 Buy ALU $7.41 $7.90 Hold
More informationMetals X Limited (MLX)
19 April 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.76 Target (12 months) $0.98 (previously $1.00) Expected Return Capital growth
More informationMesoblast (MSB) GVHD granted Fast Track, should benefit ongoing negotiations with Mallinckrodt
7 March 2017 Analyst Tanushree Jain 612 8224 2849 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $1.90 Valuation $3.22 (previously $3.17) Risk Speculative GICS Sector Pharmaceuticals
More informationBreaker Resources NL (BRB)
David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Speculative See key risks on Page 6. Speculative securities may not be suitable for retail clients 8 February 2019 Breaker NL (BRB) More
More information7.0% fully franked yield (expected 10.0% gross): Fixed until Nov 2018 reset date
6 July 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 William Spraggett 613 9235 1733 Whitefield Resettable Preference Shares (WHFPB) Authorisation John Gleeson 612 9255 7220
More informationGalaxy Resources Ltd (GXY)
27 March 2018 Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Galaxy Resources Ltd (GXY) Mt Cattlin doing what it is meant to Recommendation Buy Price $3.16 Price Target $4.75
More informationFortescue Metals Group (FMG)
30 October 2015 Analyst David Coates 612 8224 2887 Authorisation John Hester 612 8224 2871 Recommendation Buy (Hold) Price $2.09 Target (12 months) $2.40 (unchanged) Expected Return Capital growth 14.8%
More informationWestgold Resources (WGX)
7 February 2017 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $2.25 Target (12 months) $2.60 Expected Return Capital growth 15.6% Dividend
More informationPremier Investments (PMV)
4 April 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 Premier Investments (PMV) The Myers touch Recommendation Buy (unchanged) Price $14.20 Target (12 months) $17.65 (previously
More informationTalisman Mining Ltd (TLM)
Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.41 Valuation $0.88 (previously $1.00) Risk Speculative Expected Return Capital growth
More informationPioneer Credit (PNC)
23 June 2014 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 Pioneer Credit (PNC) Helping not chasing Recommendation Buy (Initiation) Price $1.55 Target (12 months) $1.80 Expected
More informationMetals X Limited (MLX)
1 November 2016 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.38 Target (12 months) $2.10 (unchanged) Expected Return Capital growth
More informationParagon Care (PGC) Big Boxes, Big Opportunity. Capitalising on the burgeoning healthcare sector. Price leadership through quality
26 September 2014 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Paragon Care (PGC) Big Boxes, Big Opportunity Recommendation Buy (Initiation) Price $0.33 Target (12 months) $0.38
More informationSt George Mining Ltd (SGQ)
Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $0.225 Valuation $0.30 (previously $0.26) Risk Speculative Expected Return Capital growth
More informationBreaker Resources NL (BRB)
Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Recommendation Buy (unchanged) Price $0.315 Valuation $0.96 (previously $1.30) Risk Speculative GICS Sector Materials Expected
More informationStrike Energy Ltd (STX)
Analyst Peter Arden 613 9235 1833 Authorisation Stuart Howe 613 9235 1782 Recommendation Buy (unchanged) Price $0.115 Valuation $0.26 (previously $0.23) Risk Speculative Expected Return Capital growth
More informationBUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS
BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD
More informationAspire Mining Ltd (AKM)
4 June 2012 Analyst Stuart Howe 613 9235 1782 Fred Truong 613 9235 1629 Authorisation Jonathan Snape 613 9235 1601 Aspire Mining Ltd (AKM) Ovoot PFS released Recommendation Buy (unchanged) Price $0.13
More informationPlatinum Asset Management
AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium
More informationValue at the top end. Figure 1: Trading margins on debt and equity securities
17 February 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Steve Goldberg 612 8224 2809 Westpac Convertible Preference Shares (WBCPC) Fixed Interest Issue overview
More informationFigure 1: ASX listed debt redemptions Figure 2: Trading margins on debt and equity securities
8 February 2017 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation (NABPE) TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code NAB NABPE Face value $100
More informationMacquarie Group Capital Notes 2 (MQGPB) * MANDATORY CONVERSION IS SUBJECT TO SATISFYING THE MANDATORY CONVERSION CONDITIONS
23 November 2015 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Macquarie Group Capital Notes 2 (MQGPB) TS Lim 612 8224 2810 Fixed Interest Issue overview Issuer Issue
More informationRide the recovery. Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call
17 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code BELL POTTER SECURITIES LIMITED ACN
More informationAsset revaluation driven by almonds
Company update 20 July 2015 RURAL FUNDS GROUP (RFF) Asset revaluation driven by almonds We retain a BUY rating with a 12-month target of $1.15 p/unit. RFF is a listed property trust with a portfolio of
More informationFigure 1: Bell Potter fair value assessment. 2.40%: July 2018 Fixed Rate Senior Bond (OTC yield 6.00%)
13 August 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation John Gleeson 612 9255 7220 Fixed Interest Issue overview Issuer Issue ASX code Crown CWNHA Face value $100
More informationIOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.
AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium
More informationBoart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index
More informationGeneration Healthcare REIT
AUSTRALIA GHC AU Price (at 06:13, 24 Aug 2015 GMT) Neutral A$1.65 Valuation - Sum of Parts A$ 1.51-1.59 12-month target A$ 1.59 12-month TSR % +1.8 Volatility Index Low GICS sector Real Estate Market cap
More informationMesoblast (MSB) Major CHF catalyst next week, Time to get on board
9 November 2018 Analyst Tanushree Jain 612 8224 2849 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $2.18 Valuation $4.06 (previously $3.95) Risk Speculative GICS Sector Pharmaceuticals
More informationSG Fleet Group. Another UK acquisition. Earnings and target price revision
AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional
More informationResetting expectations
Company update 13 May 2016 TPI ENTERPRISES (TPE) Resetting expectations We retain a BUY rating with a revised 12-month price target of $3.21 p/sh. We assess market conditions to imply a more gradual ramp
More informationTalisman Mining Ltd (TLM)
Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.29 Valuation $0.67 (previously $0.88) Risk Speculative Expected Return Capital growth
More informationCardno. Tough half over A$2.88 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA CDD AU Price (at 04:53, 17 Feb 2015 GMT) Neutral A$2.88 Valuation - Sum of Parts A$ 2.80-3.43 12-month target A$ 3.12 12-month TSR % +18.4 Volatility Index Medium GICS sector Capital Goods Market
More informationChallenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation
1H13E 2H13E 1H14E 2H14E 1H15E 2H15E AUSTRALIA CGF AU Price (at CLOSE#, 20 Aug 2012) Outperform A$3.76 Volatility index Low 12-month target A$ 4.57 12-month TSR % +26.4 Valuation - Sum of Parts A$ 4.57
More informationSG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.
AUSTRALIA SGF AU Price (at 07:57, 27 Oct 2016 GMT) Outperform A$3.85 Valuation - PER A$ 3.92-4.18 12-month target A$ 4.37 12-month TSR % +18.1 Volatility Index Medium GICS sector Commercial & Professional
More informationEclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA ECX AU Price (at 02:49, 15 Dec 2016 GMT) Outperform A$3.77 Valuation - PER A$ 3.53-3.78 12-month target A$ 4.22 12-month TSR % +16.3 Volatility Index Low/Medium GICS sector Diversified Financials
More informationSilver Chef. Capital raising A$7.71 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SIV AU Price (at 08:50, 21 Mar 2017 GMT) Neutral A$7.71 Valuation - PER A$ 6.68 12-month target A$ 6.68 12-month TSR % -7.4 Volatility Index Medium GICS sector Capital Goods Market cap A$m 278
More informationUBS Investment Research Brambles Limited
UBS Investment Research Brambles Limited FY12 result: strong revenue momentum Result highlights strong revenue momentum Brambles FY12 result was slightly ahead of expectations, revealing 11% underlying
More informationConsolidated Operations Group (COG)
Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation
More informationBank of Queensland Capital Notes (BOQPE) Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call
23 November 2017 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Bank of Queensland Capital Notes (BOQPE) TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue
More informationSims Metal Management
AUSTRALIA SGM AU Price (at 5:11, 17 Nov 215 GMT) Outperform A$7.19 Valuation - EV/EBIT A$ 8.49-9.6 12-month target A$ 8.9 12-month TSR % +26.6 Volatility Index Medium GICS sector Materials Market cap A$m
More informationMEDICAL DEVELOPMENTS INTERNATIONAL LTD
MEDICAL DEVELOPMENTS INTERNATIONAL LTD No pain in Germany HOLD Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals 6 April 2018 COMPANY UPDATE Ticker MVP Stock Price $7.10 Target Price $8.08
More informationAMP. Earnings and target price revision. No change. Price catalyst. Action and recommendation
AUSTRALIA AU Price (at CLOSE#, 19 Mar 213) Underperform A$5.7 Volatility index Low 12-month target A$ 4.99 12-month TSR % +3.6 Valuation - Sum of Parts A$ 4.68 GICS sector Insurance Market cap A$m 14,855
More informationNoni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts
Date 09 January 2018 Theme Company Update Company Noni B (NBL) BUY: FY18e EBITDA +12.8% NBL provided a positive 1H18 trading update today, advising LFL sales growth of 3.0% (1.5% in 1H17) and EBITDA of
More informationNoni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in
More informationPraemium (PPS) COMPANY REPORT. Quartermaster
10 October 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.45 SNAPSHOT Monthly Turnover $9.2mn Market Cap $162mn Shares Issued 399.6mn 52-Week High $0.54 52-Week
More informationAuckland International Airport
NEW ZEALAND AIA NZ Price (at 04:00, 27 Nov 2013 GMT) Neutral NZ$3.42 Valuation NZ$ 3.37 - DCF (WACC 8.0%, beta 0.9, ERP 7.0%, RFR 4.3%, TGR 3.0%) 12-month target NZ$ 3.37 12-month TSR % +2.6 Volatility
More informationGeneration Healthcare REIT All about spread Event
AUSTRALIA GHC AU Price (at 04:51, 14 Feb 2015 GMT) Neutral A$1.60 Valuation - Sum of Parts A$ 1.18-1.26 12-month target A$ 1.59 12-month TSR % +5.1 Volatility Index Low GICS sector Real Estate Market cap
More informationMotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts
Date Theme Company Update Company MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction We moderate to HOLD (from Buy) with a revised target of $2.36 p/share. We were previously encouraged
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Interim result draws a line in the sand Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace-lending sector. The company has
More informationRamsay Health Care. France begins to bite A$66.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst
AUSTRALIA RHC AU Price (at 06:11, 06 Aug 2015 GMT) Neutral A$66.37 Valuation A$ 64.54 - DCF (WACC 8.1%, beta 1.1, ERP 5.0%, RFR 3.8%, TGR 3.0%) 12-month target A$ 70.00 12-month TSR % +7.3 Volatility Index
More informationZip Co. Delivering against expectations. Last Price A$0.86 Target Price A$0.90 (Previously A$0.88) Recommendation Accumulate Risk Higher.
Delivering against expectations Z1P s Mar-18 qtrly report delivered well against our expectations. Positive operating cash flow for the qtr of $1.6m was a +$2.8m improvement qoq, despite the receivables
More informationSeek. Progresses Zhaopin privatisation A$16.33 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA SEK AU Price (at 06:33, 07 Apr 2017 GMT) Outperform A$16.33 Valuation - Sum of Parts A$ 16.77 12-month target A$ 16.50 12-month TSR % +3.9 Volatility Index Low/Medium GICS sector Commercial &
More informationONEVIEW HEALTHCARE PLC
ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast
More informationAutomotive Holdings Group
AUSTRALIA AHG AU Price (at 06:14, 11 Aug 2016 GMT) Outperform A$4.61 Valuation - EV/EBITA A$ 4.09-4.63 12-month target A$ 4.36 12-month TSR % -0.2 Volatility Index Low GICS sector Retailing Market cap
More informationQBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision
AUSTRALIA QBE AU Price (at 10:44, 27 Apr 2016 GMT) Neutral A$11.19 Valuation A$ - DCF (WACC 9.3%, beta 1.1, ERP 5.0%, RFR 3.8%) 11.34 12-month target A$ 12.00 12-month TSR % +12.7 Volatility Index Low/Medium
More informationAPN Property Group (APD) Buy Share Price: A$0.41
APN Property Group (APD) Buy Share Price: A$0.41 Success in direct syndicates Target Price: A$0.51 Direct property syndicates have always been an integral part of the APN Property Group (APD) business.
More informationMeridian Energy. On tax depreciation NZ$2.08 NEW ZEALAND. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
NEW ZEALAND MEL NZ Price (at 05:00, 13 Jul 2015 GMT) Outperform NZ$2.08 Valuation NZ$ 2.50 - DCF (WACC 7.8%, beta 0.6, ERP 7.0%, RFR 3.6%, TGR 2.0%) 12-month target NZ$ 2.60 12-month TSR % +31.7 Volatility
More informationSpotless Group Holdings
AUSTRALIA SPO AU Price (at 05:45, 31 Jan 2017 GMT) Neutral A$0.94 Valuation - Peer multiples A$ 1.02 12-month target A$ 1.02 12-month TSR % +18.3 Volatility Index High GICS sector Commercial & Professional
More informationTox Free Solutions. Winning work again A$2.34 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation
AUSTRALIA TOX AU Price (at 05:10, 30 Nov 2016 GMT) Outperform A$2.34 Valuation - EV/EBITDA A$ 2.52-3.07 12-month target A$ 2.79 12-month TSR % +23.1 Volatility Index Medium GICS sector Commercial & Professional
More informationVista Group International
NEW ZEALAND VGL NZ Price (at 03:15, 26 Feb 2015 GMT) Outperform NZ$4.35 Valuation NZ$ 4.31 - DCF (WACC 9.9%, beta 1.0, ERP 7.0%, RFR 4.0%, TGR 2.0%) 12-month target NZ$ 4.75 12-month TSR % +9.5 Volatility
More informationSuper Retail Group (SUL AU) Are we there yet?
25 October 2018 Australia EQUITIES SUL AU Price (at 09:01, 24 Oct 2018 GMT) Neutral A$8.33 Valuation A$ 8.30-9.50 - EV/EBITA 12-month target A$ 8.70 12-month TSR % +10.9 Volatility Index GICS sector Low/Medium
More informationPRICE $1.30 Regional Express Holdings Ltd REX
16 November 2006 PRICE $1.30 Regional Express Holdings Ltd REX Analyst Ken Fleming (03) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (03) 6224 9899 Fully diluted shares on issue 115M Market cap A$133M
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The
More informationWINDLAB LTD HOLD. Lakeland financial close delayed again. Downgrade to HOLD. COMPANY UPDATE EVENT IMPACT INVESTMENT VIEW
WINDLAB LTD HOLD Lakeland financial close delayed again. Downgrade to HOLD. Utilities / Renewable Electricity 7 November 2018 COMPANY UPDATE Ticker WND Stock Price $1.180 Target Price $1.350 Forecast Capital
More informationFisher & Paykel Healthcare
NEW ZEALAND FPH NZ Price (at 05:00, 10 Jul 2015 GMT) Outperform NZ$7.03 Valuation NZ$ 7.39 - DCF (WACC 8.8%, beta 0.9, ERP 7.0%, RFR 4.5%, TGR 2.0%) 12-month target NZ$ 7.80 12-month TSR % +13.1 Volatility
More informationAustralian Banks. Funding markets open for now
AUSTRALIA Weekly performance 4% 2% % -2% -4% -6% -8% -1% Source: IRESS, August 212 Rolling monthly performance 8% 6% 4% 2% % -2% -4% -6% Source: IRESS, August 212 Rolling yearly performance % 15% 5% -5%
More informationInvocare. Well-positioned. Earnings and target price revision. Price catalyst. Catalyst: FY12 results. Action and recommendation
AUSTRALIA IVC AU Close Price* 19 Jan 12 Outperform A$7.54 Volatility index Low 12-month target A$ 8.3 12-month TSR % +14.6 Valuation A$ 8.28 - DCF GICS sector Consumer Services Market cap A$m 83 3-day
More informationAtCor Medical Holdings Limited (ACG)
Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary
More informationKingsgate Consolidated
AUSTRALIA KCN AU Price (at 6:11, 31 Jul 215 GMT) Underperform A$.67 Valuation A$ - DCF (WACC 12.%, beta 1.6, ERP 5.%, RFR 3.8%).3 12-month target A$.3 12-month TSR % -54.9 Volatility Index Very High GICS
More informationRegional Express Holdings Ltd REX
20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last
More informationAventus Retail Property Fund
AUSTRALIA AVN AU Price (at 06:10, 29 Apr 2016 GMT) A$2.16 Volatility Index Low GICS sector Real Estate Market cap A$m 741 30-day avg turnover A$m 0.7 Number shares on issue m 343.2 Investment fundamentals
More information